Navigation Links
Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
Date:9/5/2007

PRINCETON, N.J., Sept. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced the extension of a broad antibody development relationship with its licensing partner, Centocor R&D, Inc. The extended relationship provides Centocor with continued access to Medarex's UltiMAb Human Antibody Development System(R) for the generation of fully human antibodies to an unlimited number of targets.

Under the terms of the new agreement, Centocor will license Medarex's UltiMAb(R) technology to discover and potentially develop and commercialize fully human antibody therapeutics. Medarex expects to receive license fees and milestone payments as well as royalties on commercial sales of any products that may result from this agreement. No further financial terms of the agreement were disclosed.

Centocor first licensed the UltiMAb technology in 1997, and an expanded agreement was announced in 2000.

"We are delighted with the opportunity to continue our relationship with Centocor," said Howard H. Pien, President and CEO of Medarex. "We have been pleased to be a partner to Centocor in its development of UltiMAb antibodies into potentially very important products, and we look forward to the extension of this partnership into the future."

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human anti
'/>"/>

SOURCE Medarex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
Breaking Biology News(10 mins):Researchers demonstrate nanoscale X-ray imaging of bacterial cells 2AACR names Perou 2009 Outstanding Investigator for Breast Cancer Research 2Genome BC collaborates with Chile and Norway to sequence salmon genome 2Los Angeles Kerlan Jobe Orthopaedic Clinic Pays 243 Million to Settle Kickback Allegations 62394 1Los Angeles Kerlan Jobe Orthopaedic Clinic Pays 243 Million to Settle Kickback Allegations 62394 2Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 1Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 2Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 3Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 4Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 5Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 6Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 7Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 8Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 9Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 10Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 11Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 12Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 13Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 14Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 15Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 16Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 17Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 18Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 19Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 20Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 21Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 22Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 23Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 24Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 25Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 26Reportlinker Adds Emerging Clinical Trial Locations Eastern Europe 3A Market Dynamics and the Changing Healthcare and Regulatory Environment 15031 27Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 1Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 2Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 3Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 4Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 5Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 6Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 7Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 8Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 9Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 10Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 11Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 12Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 13Reportlinker Adds HPLC Systems 26amp 3B Accessories A World Market Review 6658 14